Invesco
DAWN

Invesco’s Day One Biopharmaceuticals DAWN Stock Holding History

Invesco’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.43M Buy
159,898
+35,904
+29% +$506K ﹤0.01% 2328
2025
Q4 		$1.16M Buy
123,994
+25,952
+26% +$217K ﹤0.01% 2850
2025
Q3 		$691K Buy
98,042
+29,535
+43% +$203K ﹤0.01% 3103
2025
Q2 		$445K Buy
68,507
+22,083
+48% +$152K ﹤0.01% 3203
2025
Q1 		$368K Buy
46,424
+13,636
+42% +$147K ﹤0.01% 3282
2024
Q4 		$415K Buy
32,788
+798
+2% +$11.1K ﹤0.01% 3316
2024
Q3 		$446K Buy
31,990
+766
+2% +$10.9K ﹤0.01% 3280
2024
Q2 		$430K Sell
31,224
-419
-1% -$6.13K ﹤0.01% 3338
2024
Q1 		$523K Buy
31,643
+285
+0.9% +$4.26K ﹤0.01% 3313
2023
Q4 		$458K Buy
31,358
+12,196
+64% +$148K ﹤0.01% 3273
2023
Q3 		$235K Buy
19,162
+3,068
+19% +$40K ﹤0.01% 3535
2023
Q2 		$192K Buy
+16,094
New +$210K ﹤0.01% 3623
2022
Q3 		– Sell
-97,024
Closed -$1.74M – 4001
2022
Q2 		$1.74M Buy
+97,024
New +$1M ﹤0.01% 2766

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Invesco's DAWN Position: Q1 2026 in Review

Invesco increased its Day One Biopharmaceuticals (DAWN) stake by 29% in Q1 2026, buying an estimated $506K and bringing the position to 159,898 shares worth $3.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2328.

Invesco first reported a position in DAWN in Q2 2022 and has held it in 13 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Invesco held 159,898 shares of Day One Biopharmaceuticals worth $3.43M as of Q1 2026.
  • Invesco bought 35,904 Day One Biopharmaceuticals shares in Q1 2026, an estimated $506K.
  • Day One Biopharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2328 holding.
  • Invesco first reported a position in Day One Biopharmaceuticals in Q2 2022 and has held it in 13 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.